{"id":"https://openalex.org/W2174757490","doi":"https://doi.org/10.1016/s0960-894x(02)01020-x","title":"Imidazopyrimidines, potent inhibitors of p38 MAP kinase","display_name":"Imidazopyrimidines, potent inhibitors of p38 MAP kinase","alternate_titles":[],"publication_year":2003,"publication_date":"2003-02-01","ids":{"openalex":"https://openalex.org/W2174757490","doi":"https://doi.org/10.1016/s0960-894x(02)01020-x","mag":"2174757490","pmid":"https://pubmed.ncbi.nlm.nih.gov/12565927"},"language":"en","primary_location":{"id":"doi:10.1016/s0960-894x(02)01020-x","doi":"https://doi.org/10.1016/s0960-894x(02)01020-x","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s0960-894x(02)01020-x","pdf_url":null,"source":{"id":"https://openalex.org/S30970080","display_name":"Bioorganic & Medicinal Chemistry Letters","issn_l":"0960-894X","issn":["0960-894X","1464-3405"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic &amp; Medicinal Chemistry Letters","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2174757490"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5091119636","display_name":"Kenneth C. Rupert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Kenneth C Rupert","raw_affiliation_strings":["Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA. krupert@prdus.jnj.com","Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA. krupert@prdus.jnj.com","institution_ids":["https://openalex.org/I4405282460"]},{"raw_affiliation_string":"Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065152783","display_name":"James R. Henry","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"James R Henry","raw_affiliation_strings":["Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035006405","display_name":"John H. Dodd","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"John H Dodd","raw_affiliation_strings":["Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104109911","display_name":"Scott A. Wadsworth","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Scott A Wadsworth","raw_affiliation_strings":["Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111422789","display_name":"DRUIE E. CAVENDER","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Druie E Cavender","raw_affiliation_strings":["Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005925064","display_name":"Gilbert C. Olini","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gilbert C Olini","raw_affiliation_strings":["Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112445136","display_name":"Bohumila Fahmy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Bohumila Fahmy","raw_affiliation_strings":["Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5063761193","display_name":"John J. Siekierka","orcid":"https://orcid.org/0000-0002-0269-0960","observed_orcids":["https://orcid.org/0000-0002-0269-0960"]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"John J Siekierka","raw_affiliation_strings":["Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA","institution_ids":["https://openalex.org/I4405282460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5065152783","https://openalex.org/A5091119636"],"corresponding_institution_ids":["https://openalex.org/I4405282460"],"apc_list":{"value":3880,"currency":"USD","value_usd":3880},"apc_paid":null,"fwci":0.7705,"has_fulltext":false,"cited_by_count":276,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.6338942,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":99,"max":100},"biblio":{"volume":"13","issue":"3","first_page":"347","last_page":"350"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.5205000042915344,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.5205000042915344,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":0.19449999928474426,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.12269999831914902,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/imidazopyrimidines","display_name":"imidazopyrimidines","score":0.996999979019165},{"id":"https://openalex.org/keywords/p38-mapk","display_name":"p38 MAPK","score":0.8610000014305115},{"id":"https://openalex.org/keywords/kinase-inhibitors","display_name":"kinase inhibitors","score":0.8550000190734863},{"id":"https://openalex.org/keywords/tnf-alpha","display_name":"TNF-\u03b1","score":0.972000002861023},{"id":"https://openalex.org/keywords/interleukin-1beta","display_name":"IL-1\u03b2","score":0.824999988079071},{"id":"https://openalex.org/keywords/pro-inflammatory-cytokines","display_name":"inflammatory cytokines","score":0.9139999747276306},{"id":"https://openalex.org/keywords/rheumatoid-arthritis","display_name":"rheumatoid arthritis","score":0.8579999804496765},{"id":"https://openalex.org/keywords/crohn-s-disease","display_name":"Crohn's disease","score":0.9729999899864197},{"id":"https://openalex.org/keywords/anti-inflammatory-agents","display_name":"anti-inflammatory agents","score":0.5989999771118164}],"concepts":[{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.7246764302253723},{"id":"https://openalex.org/C51551487","wikidata":"https://www.wikidata.org/wiki/Q2043632","display_name":"p38 mitogen-activated protein kinases","level":4,"score":0.6967743635177612},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.6734035015106201},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.6674231290817261},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.6399639248847961},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.559813916683197},{"id":"https://openalex.org/C132149769","wikidata":"https://www.wikidata.org/wiki/Q899651","display_name":"Mitogen-activated protein kinase","level":3,"score":0.5468558073043823},{"id":"https://openalex.org/C2777077863","wikidata":"https://www.wikidata.org/wiki/Q170990","display_name":"Arthritis","level":2,"score":0.5318688154220581},{"id":"https://openalex.org/C17991360","wikidata":"https://www.wikidata.org/wiki/Q21173843","display_name":"Tumor necrosis factor alpha","level":2,"score":0.5043896436691284},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.48718780279159546},{"id":"https://openalex.org/C2778260677","wikidata":"https://www.wikidata.org/wiki/Q917447","display_name":"Inflammatory bowel disease","level":3,"score":0.4628993272781372},{"id":"https://openalex.org/C97029542","wikidata":"https://www.wikidata.org/wiki/Q281417","display_name":"Protein kinase A","level":3,"score":0.25811976194381714},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2443070411682129},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.22458580136299133},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.13903087377548218},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.13542792201042175},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.1117105484008789},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.07988455891609192},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D002384","descriptor_name":"Catalysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D007202","descriptor_name":"Indicators and Reagents","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014409","descriptor_name":"Tumor Necrosis Factor-alpha","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D020928","descriptor_name":"Mitogen-Activated Protein Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D048051","descriptor_name":"p38 Mitogen-Activated Protein Kinases","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/s0960-894x(02)01020-x","doi":"https://doi.org/10.1016/s0960-894x(02)01020-x","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s0960-894x(02)01020-x","pdf_url":null,"source":{"id":"https://openalex.org/S30970080","display_name":"Bioorganic & Medicinal Chemistry Letters","issn_l":"0960-894X","issn":["0960-894X","1464-3405"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic &amp; Medicinal Chemistry Letters","raw_type":"journal-article"},{"id":"pmid:12565927","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12565927","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic & medicinal chemistry letters","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":14,"referenced_works":["https://openalex.org/W1921708445","https://openalex.org/W1940987942","https://openalex.org/W1970438308","https://openalex.org/W1985177300","https://openalex.org/W2010900664","https://openalex.org/W2014018845","https://openalex.org/W2016032857","https://openalex.org/W2017040808","https://openalex.org/W2042076664","https://openalex.org/W2042498574","https://openalex.org/W2043093261","https://openalex.org/W2071029740","https://openalex.org/W2121537979","https://openalex.org/W2949496522"],"related_works":["https://openalex.org/W2051882214","https://openalex.org/W2016032857","https://openalex.org/W2111494666","https://openalex.org/W167972162","https://openalex.org/W1970721128","https://openalex.org/W2119691056","https://openalex.org/W2042464158","https://openalex.org/W1965193622","https://openalex.org/W4240861804","https://openalex.org/W3117963022"],"abstract_inverted_index":null,"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2174757490","counts_by_year":[{"year":2026,"cited_by_count":11},{"year":2025,"cited_by_count":13},{"year":2024,"cited_by_count":14},{"year":2023,"cited_by_count":19},{"year":2022,"cited_by_count":10},{"year":2021,"cited_by_count":17},{"year":2020,"cited_by_count":21},{"year":2019,"cited_by_count":20},{"year":2018,"cited_by_count":12},{"year":2017,"cited_by_count":18},{"year":2016,"cited_by_count":20},{"year":2015,"cited_by_count":21},{"year":2014,"cited_by_count":20},{"year":2013,"cited_by_count":13},{"year":2012,"cited_by_count":14}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
